| ABYEX | RNWAX | ABYEX / RNWAX | |
| Total Expense Ratio | 1.00 | 1.66 | 60% |
| Annual Report Gross Expense Ratio | 1.40 | 1.66 | 84% |
| Fund Existence | 15 years | 24 years | - |
| Gain YTD | 17.040 | 13.362 | 128% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 250 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 173M | 90.7B | 0% |
| Annual Yield % from dividends | 2.69 | 0.50 | 541% |
| Returns for 1 year | 28.94 | 20.44 | 142% |
| Returns for 3 years | 72.33 | 39.97 | 181% |
| Returns for 5 years | 40.87 | 12.95 | 316% |
| Returns for 10 years | 92.29 | 98.52 | 94% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| CLIQX | 26.56 | 0.23 | +0.87% |
| Lone Peak Value Super Institutional | |||
| PRPCX | 5.41 | 0.03 | +0.56% |
| PGIM Jennison Energy Infrastructure C | |||
| IGA | 10.21 | 0.04 | +0.39% |
| Voya Global Advantage AND Premium Opportunity Fund | |||
| TBLIX | 37.58 | 0.14 | +0.37% |
| Transamerica Multi-Managed Balanced I | |||
| FTXH | 38.89 | -0.41 | -1.05% |
| First Trust Nasdaq Pharmaceuticals ETF | |||